💉 Modeling Vaccination Impact: The Susceptible–Vaccinated–Infectious–Recovered (SVIR) Framework

The SVIR compartmental model extends the classical SIR structure to explicitly capture the dynamics of vaccination—an essential tool for evaluating public health interventions against infectious diseases. By integrating a vaccinated class, this framework enables rigorous quantification of how immunization campaigns alter transmission pathways, shift herd immunity thresholds, and inform optimal vaccine deployment strategies.


🗂️ Compartmental Structure

The total population N(t) = S(t) + V(t) + I(t) + R(t) is partitioned into four mutually exclusive states:

  • Susceptible (S): Individuals who can contract the disease; they transition to I upon infection or to V upon vaccination.
  • Vaccinated (V): Individuals who have received a vaccine. In the baseline model, they gain partial or full immunity, depending on vaccine efficacy.
  • Infectious (I): Infected individuals who are capable of transmitting the pathogen.
  • Recovered (R): Individuals who have cleared the infection and are assumed immune (at least over the modeling horizon).

💡 Note: The model can be extended to include waning immunity (V → S or R → S), breakthrough infections (V → I), or multi-dose schedules.


🧮 Mathematical Formulation (Deterministic ODE System)

Assuming a closed population with mass-action transmission and constant total size (no vital dynamics), the core SVIR dynamics are governed by:

dS/dt = -(β S I)/N - ω S  
dV/dt = ω S - ζ V  
dI/dt = (β S I)/N - γ I  
dR/dt = γ I + ζ V  

Key parameters:

  • β: Transmission rate (per contact per unit time)
  • ω: Vaccination rate (fraction of susceptibles vaccinated per unit time)
  • γ: Recovery rate (inverse of infectious period)
  • ζ: Rate at which vaccinated individuals gain full, stable immunity (if ζ = 0, V is a terminal immune state; if modeling waning immunity, a term δ V may feed back to S)

For imperfect vaccines with efficacy ε ∈ [0,1], the force of infection on vaccinated individuals is reduced by (1 – ε), or the compartment V may include a sub-flow to I at rate (1 – ε)(β V I)/N.


📈 Plausible Parameter Ranges (General Viral Disease Context)

ParameterSymbolTypical RangeInterpretation
Transmission rateβ0.3 – 2.5 day⁻¹Varies by pathogen (e.g., higher for measles, lower for seasonal flu)
Recovery rateγ0.1 – 0.5 day⁻¹Corresponds to infectious period of 2–10 days
Basic reproduction numberR₀ = β/γ1.2 – 18Measles: ~12–18; Influenza: ~1.3; SARS-CoV-2 (ancestral): ~2.5–4
Vaccination rateω0.001 – 0.1 day⁻¹Reflects campaign intensity (e.g., 0.01 = 1% of susceptibles vaccinated daily)
Vaccine efficacyε0.4 – 0.95mRNA vaccines vs. SARS-CoV-2: ~0.9; Influenza vaccines: ~0.4–0.6

⚠️ These values are context-dependent and must be calibrated to specific outbreaks, regions, and vaccine types.


⚖️ Applicability & Key Limitations

When to use SVIR:

  • Evaluating mass vaccination campaigns in closed or semi-closed populations
  • Estimating critical vaccination coverage needed for herd immunity
  • Formulating optimal control problems for vaccine allocation
  • Studying diseases where infection confers long-term immunity

Key limitations:

  • Assumes homogeneous mixing (ignores contact networks, spatial heterogeneity)
  • Baseline model presumes instantaneous, lifelong immunity post-vaccination (often unrealistic)
  • Does not distinguish between asymptomatic/presymptomatic transmission
  • Lacks age or risk-stratification unless extended (e.g., multi-group SVIR)
  • Cannot capture immune escape or variant-driven changes in β or ε without time-varying parameters

🔍 For realistic policy analysis, SVIR is often embedded in stochastic, age-structured, or network-based frameworks.


📖 Key References

  1. Liu, X., Takeuchi, Y., & Iwami, S. (2008). SVIR epidemic models with vaccination strategies. Journal of Theoretical Biology.
  2. Turkyilmazoglu, M. (2022). An extended epidemic model with vaccination: Weak-immune SIRVI. Chaos, Solitons & Fractals.
  3. Enayati, S., & Ozaltin, O. Y. (2020). Optimal influenza vaccine distribution with equity. European Journal of Operational Research.
  4. Saad-Roy, C. M., Wagner, C. E., et al. (2020). Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science.
  5. Tuong, T. D., Nguyen, D. H., & Nguyen, N. N. (2024). Stochastic multi-group epidemic SVIR models: Degenerate case. Journal of Mathematical Analysis and Applications.

Leave a Comment